Clinical trials: Suspected Alzheimer's Disease (AD)
Suspected Typical Alzheimer's Disease (AD), Suspected Atypical Alzheimer's Disease (AD)
VIdeo Telehealth in ALzheimer's: NeuroPsychology (VITAL-NP)
The overarching goal of this study is to a) assess the feasibility and preliminary validity of home-based delivery of TeleNP to patients with suspected Alzheimer's Disease (AD), referred for cognitive assessments in a Neurology…
- Trial name
- VITAL-NP (NCT05379023)
- Testing
- Face-to-face evaluation (FF), TeleNP evaluation
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- University of Colorado, Denver
Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS)
[18F]ACI-19626 PET in TDP-43 Proteinopathies
The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein TDP-43 [involved in rare forms of dementia such as frontotemporal dementia (FTD) and in amyotrophic…
- Conditions
- Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS), TDP-43 Proteinopathies, Suspected Limbic Predominant Age-related TDP-43 Encephalopathy (LATE)
- Trial name
- NCT06891716
- Testing
- [18F]ACI-19626
- Where
- Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AC Immune SA
Suspected Chronic Traumatic Encephalopathy (CTE) or Traumatic Encephalopathy Syndrome (TES), Suspected Alzheimer's Disease (AD)
FDDNP Protocol for Visualizing Brain Proteinopathies to Assist in the Diagnosis of Persons With Suspected CTE and AD
The primary objective of this study is to demonstrate the safety and efficacy of positron emission tomography (PET) imaging with a radioactive compound called [F-18]FDDNP in subjects with suspected Alzheimer's disease or…
- Trial name
- FDDNP (NCT04311281)
- Testing
- [F-18]FDDNP-PET
- Sponsor
- University of California, Los Angeles
Alzheimer Disease
Study of the Indications for Amyloid Positon Emission Tomography (PET) Scans and Their Usefulness for Patients With Suspected Alzheimer's Disease (AD)
The recent clinical authorization of amyloid Positon Emission Tomography (PET) in France represents a crucial step for the nuclear medicine community involved in the diagnosis of Alzheimer's disease (AD).
- Trial name
- TEPAmy (NCT06467981)
- Testing
- Retrospective study
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Central Hospital, Nancy, France